Skip to main content

Research Repository

Advanced Search

Outputs (582)

Smoking is a risk factor for autoimmune hepatitis: An English registry-based case-control study (2024)
Journal Article
Grønbæk, L., Omeife, H., Ban, L., Crooks, C. J., Card, T. R., Jepsen, P., & West, J. (2024). Smoking is a risk factor for autoimmune hepatitis: An English registry-based case-control study. Clinical Epidemiology, 16, 23-30. https://doi.org/10.2147/CLEP.S439219

Purpose: Smoking is a risk factor for some autoimmune diseases, but its association with autoimmune hepatitis remains unknown. We conducted a population-based matched case–control study to examine the association between tobacco smoking and the risk... Read More about Smoking is a risk factor for autoimmune hepatitis: An English registry-based case-control study.

A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms (2024)
Journal Article
Zareian, N., Eremin, O., Pandha, H., Baird, R., Kwatra, V., Funingana, G., …Spicer, J. (2024). A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms. Experimental Biology and Medicine, 249(1), https://doi.org/10.3389/ebm.2024.10021

The presence of inhibitory immune cells and difficulty in generating activated effector T cells remain obstacles to development of effective cancer vaccines. We designed a vaccine regimen combining human telomerase reverse transcriptase (hTERT) pepti... Read More about A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms.

A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes. (2023)
Journal Article
Ng, C., Dellschaft, N. S., Hoad, C., Marciani, L., Spiller, R., Crooks, C., …Smyth, A. R. (2023). A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes. NIHR Open Research, 3(65), 1-16. https://doi.org/10.3310/nihropenres.13510.1

Background People with cystic fibrosis (CF) can experience recurrent chest infections, pancreatic exocrine insufficiency and gastrointestinal symptoms. New cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs improve lung fun... Read More about A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes..

PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease (2023)
Journal Article
Nielsen, M. J., Dolman, G. E., Harris, R., Frederiksen, P., Chalmers, J., Grove, J. I., …Guha, I. N. (2023). PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease. JHEP Reports, 5(6), Article 100743. https://doi.org/10.1016/j.jhepr.2023.100743

Background & Aims: Fibroblast activity is a key feature of fibrosis progression and organ function loss, leading to liver-related complications and mortality. The fibrogenesis marker, PRO-C3, has been shown to have prognostic significance in relation... Read More about PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease.

Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial (2023)
Journal Article
Gunn, D., Topan, R., Barnard, L., Fried, R., Holloway, I., Brindle, R., …Spiller, R. (2023). Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. Alimentary Pharmacology and Therapeutics, 57(11), 1258-1271. https://doi.org/10.1111/apt.17426

Summary: Background: Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS‐D). Aim: To conduct a 12‐week parallel group, randomised, double‐blind, placebo‐controlled trial of ondansetron 4 mg o.d. (titrated up to 8 mg t.d.s.)... Read More about Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial.

A comparative, randomised MRI study of the physiological and appetitive responses to gelling (alginate) and non-gelling nasogastric tube feeds in healthy men (2023)
Journal Article
Aliyu, A. I., Nixon, A., Hoad, C., Marciani, L., Corsetti, M., Aithal, G. P., …Taylor, M. A. (2023). A comparative, randomised MRI study of the physiological and appetitive responses to gelling (alginate) and non-gelling nasogastric tube feeds in healthy men. British Journal of Nutrition, 130(8), 1316-1328. https://doi.org/10.1017/S0007114523000302

AbstractInclusion in nasogastric tube feeds (NGTF) of acid-sensitive, seaweed-derived alginate, expected to form a reversible gel in the stomach, may create a more normal intragastric state and modified gastrointestinal responses. This may ameliorate... Read More about A comparative, randomised MRI study of the physiological and appetitive responses to gelling (alginate) and non-gelling nasogastric tube feeds in healthy men.

Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK (2023)
Journal Article
Hamill, V., Gelson, W., MacDonald, D., Richardson, P., Ryder, S. D., Aldersley, M., …Innes, H. (2023). Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK. Liver International, 43(4), 917-927. https://doi.org/10.1111/liv.15528

Background: Previous studies show the uptake of biannual ultrasound (US) surveillance in patients with cirrhosis is suboptimal. Here, our goal was to understand in broader terms how surveillance is being delivered to cirrhosis patients with cured hep... Read More about Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK.

Discovery of a polymer resistant to bacterial biofilm, swarming, and encrustation (2023)
Journal Article
Dubern, J. F., Hook, A. L., Carabelli, A. M., Chang, C. Y., Lewis-Lloyd, C. A., Luckett, J. C., …Williams, P. (2023). Discovery of a polymer resistant to bacterial biofilm, swarming, and encrustation. Science Advances, 9(4), Article eadd7474. https://doi.org/10.1126/sciadv.add7474

Innovative approaches to prevent catheter-associated urinary tract infections (CAUTIs) are urgently required. Here, we describe the discovery of an acrylate copolymer capable of resisting single- and multispecies bacterial biofilm formation, swarming... Read More about Discovery of a polymer resistant to bacterial biofilm, swarming, and encrustation.

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated (2023)
Journal Article
Atallah, E., Grove, J., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., …Aithal, G. (2023). Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology, 78(5), 989-997. https://doi.org/10.1016/j.jhep.2022.12.034

Background & Aims The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-re... Read More about Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.

Patient and Public Involvement and Engagement for PhD Students (2023)
Working Paper
Gladman, J. R. F., Stocks, J., Phillips, B., Horobin, A., Wragg, A., Mundey, M., …Humes, D. (2022). Patient and Public Involvement and Engagement for PhD Students

This paper aims to provide useful advice regarding the development of skills for patient and public involvement and engagement (PPIE) in research. The authors of this paper comprise experienced PhD supervisors and trainers, researchers leading PPIE a... Read More about Patient and Public Involvement and Engagement for PhD Students.